Agios Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript
Good afternoon, everyone. I'm Salveen Richter, one of the biotechnology analysts at Goldman Sachs.
And we're pleased to have the Agios team here with us. So we have Jackie Fouse, CEO; and Andrew Hirsch, CFO.
Questions & Answers
Maybe to start here, you could walk us through the long-term strategy for Agios. You've got 2 commercial drugs. You've got label expansions on TAP and a pretty broad research pipeline. So looking forward, how do you continue executing in a focused manner while you expand the pipeline here with these opportunities?
Yes. Salveen, I guess the first thing I would say is you come into a terrific company, position of strength, you just don't want to mess it up, right? So I think that's one thing. But we're going to continue to -- the Agios' tradition of following the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
